R&D
Amylyx’s Bet on a GLP-1 ‘Blocker’ Pays Off in Post-Surgery Low Blood Sugar
While the industry chases GLP-1 agonists for weight loss, Amylyx went the other way — and its GLP-1 antagonist cut severe hypoglycemic events by 55% in a late-stage trial.